| 1 | we would need to | | | | | | | 3 | 0.33% |
| 2 | be able to run | | | | | | | 2 | 0.22% |
| 3 | the clinical trial ecosystem | | | | | | | 2 | 0.22% |
| 4 | toward a common goal | | | | | | | 2 | 0.22% |
| 5 | clinical trials for patients | | | | | | | 2 | 0.22% |
| 6 | fundamental purpose – to | | | | | | | 1 | 0.11% |
| 7 | gave our platform a | | | | | | | 1 | 0.11% |
| 8 | our platform a name | | | | | | | 1 | 0.11% |
| 9 | platform a name that | | | | | | | 1 | 0.11% |
| 10 | a name that reinforced | | | | | | | 1 | 0.11% |
| 11 | name that reinforced its | | | | | | | 1 | 0.11% |
| 12 | that reinforced its more | | | | | | | 1 | 0.11% |
| 13 | reify health logo care | | | | | | | 1 | 0.11% |
| 14 | we gave our platform | | | | | | | 1 | 0.11% |
| 15 | – to bring the | | | | | | | 1 | 0.11% |
| 16 | to bring the workflows | | | | | | | 1 | 0.11% |
| 17 | bring the workflows of | | | | | | | 1 | 0.11% |
| 18 | the workflows of key | | | | | | | 1 | 0.11% |
| 19 | workflows of key clinical | | | | | | | 1 | 0.11% |
| 20 | of key clinical trial | | | | | | | 1 | 0.11% |
| 21 | stakeholders together the “study | | | | | | | 1 | 0.11% |
| 22 | together the “study team” | | | | | | | 1 | 0.11% |
| 23 | the “study team” onto | | | | | | | 1 | 0.11% |
| 24 | purpose – to bring | | | | | | | 1 | 0.11% |
| 25 | journey we gave our | | | | | | | 1 | 0.11% |
| 26 | team” onto a common | | | | | | | 1 | 0.11% |
| 27 | on a common technology | | | | | | | 1 | 0.11% |
| 28 | us and the industry | | | | | | | 1 | 0.11% |
| 29 | and the industry what | | | | | | | 1 | 0.11% |
| 30 | the industry what was | | | | | | | 1 | 0.11% |
| 31 | industry what was possible | | | | | | | 1 | 0.11% |
| 32 | what was possible when | | | | | | | 1 | 0.11% |
| 33 | clinical trial stakeholders collaborate | | | | | | | 1 | 0.11% |
| 34 | trial stakeholders collaborate on | | | | | | | 1 | 0.11% |
| 35 | stakeholders collaborate on a | | | | | | | 1 | 0.11% |
| 36 | collaborate on a common | | | | | | | 1 | 0.11% |
| 37 | platform but critically this | | | | | | | 1 | 0.11% |
| 38 | longer journey we gave | | | | | | | 1 | 0.11% |
| 39 | but critically this was | | | | | | | 1 | 0.11% |
| 40 | critically this was always | | | | | | | 1 | 0.11% |